Universal Health Services, Inc. (UHS) $181.38
Universal Health Services (UHS) finds itself at a critical juncture, trading deep in oversold territory with a significant analyst-backed upside. This healthcare stalwart now presents a compelling entry window for investors seeking a high-conviction dip.
52-wk High $246.33
π Investment Snapshot
- π° Trading at $181.38, UHS carries an attractive 7.85x P/E, significantly below the S&P 500 average.
- π Q4 2025 revenue hit $4.49B with EPS of $7.01, demonstrating consistent top and bottom-line growth.
- π The stock is deeply oversold (RSI 28.1) and sits within a key bullish Fair Value Gap, signaling a potential reversal.
- π― Analysts maintain a Buy consensus with a mean target of $248.76, implying a +37.15% upside.
UHS currently trades at a substantial discount, driven by recent market headwinds, yet its underlying fundamentals remain robust. The confluence of extreme oversold conditions and a clear bullish FVG near current price establishes a strong technical foundation for a rebound.
| π Entry Zone | $178.00 – $181.00 | π Stop-Loss | $175.00 |
| π Adjust If | A sustained break below $175.00 on above-average volume would invalidate the current bullish thesis. | ||
The Investment Case β Why Now?
UHS has seen a significant pullback over the last three months, shedding 18.1% of its value and pushing it into deeply oversold territory. This decline, despite healthy quarterly earnings and a low P/E multiple, creates a compelling entry point for value-oriented investors. The market appears to be overreacting to broader sector pressures, overlooking UHS’s consistent operational performance.
The primary risk to this thesis lies in the company’s capital allocation strategy, specifically the recent trend of buybacks exceeding free cash flow. While share repurchases can be accretive, a continued reliance on debt or dwindling cash reserves to fund them could erode financial flexibility and pressure future growth initiatives. This warrants close monitoring.
π€ Given the recent price weakness, are investors underestimating the resilience of UHS’s healthcare services demand, or is the market accurately pricing in potential margin pressures?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | Universal Health Services, Inc. |
| Ticker / Exchange | UHS / NYSE |
| Sector / Industry | Healthcare / Medical Care Facilities |
| CEO | Marc D. Miller |
| Founded / HQ | 1979 / King of Prussia, PA |
π Price Action & Technicals
Inside VA
The most recent liquidity sweep was a sell-side sweep at $213.22 on February 6, 2026, indicating institutional selling pressure at higher levels.
UHS’s price action reveals a clear downtrend, with the stock trading significantly below both its 50-day ($202.52) and 200-day ($200.41) Simple Moving Averages. These moving averages now act as formidable resistance levels, requiring a substantial buying impulse to overcome. The current price also sits near the lower Bollinger Band, suggesting a potential short-term bounce is due.
The Relative Strength Index (RSI) at 28.1 screams deeply oversold, a condition that historically precedes at least a temporary relief rally. However, the ADX at 42.9, with a dominant -DI (30.1 vs +DI 13.7), confirms a strong bearish trend is firmly in place, indicating that any bounce might face significant overhead supply. The MACD, while still negative, shows its line above the signal, hinting at a slight easing of bearish momentum.
From a volume profile perspective, the stock currently trades within its Value Area ($163.17-$230.85) but well below the Point of Control (POC) at $225.21. This suggests that the majority of recent trading activity occurred at much higher prices, implying potential resistance as the stock attempts to climb. The Anchored VWAP from July 2025 earnings at $202.55 further reinforces this overhead supply.
Volume has been exceptionally low, running at only 30% of its 20-day average, which raises concerns about the conviction behind any price moves. While the presence of an open bullish FVG at $178.09-$181.05 provides immediate support, the lack of strong buying volume could make a sustained reversal challenging. The Technical Confluence Score of 70/100, while moderate, reflects mixed signals, with the FVG offering a key bullish counterpoint to the bearish VWAP and ADX readings.
π€ With the stock deeply oversold but still under a strong bearish trend, what specific technical trigger would confirm a sustainable reversal rather than just a dead cat bounce?
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| UHS | Universal Health Services | 7.85x |
| HCA | HCA Healthcare | 11.2x |
| THC | Tenet Healthcare | 8.5x |
| LPNT | LifePoint Health | 9.1x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $4.49B | $7.01 | |
| Q3 2025 | $4.50B | $5.86 | |
| Q2 2025 | $4.28B | $5.43 | |
| Q1 2025 | $4.10B | $4.80 |
UHS generated $0.3 billion in free cash flow in the latest quarter, which was notably outpaced by $0.4 billion in share buybacks. While buybacks can enhance shareholder value, this trend of repurchases exceeding FCF warrants careful observation for long-term financial health.
UHS consistently delivers solid quarterly results, with revenue steadily climbing from $4.10 billion in Q1 2025 to $4.49 billion in Q4 2025. Earnings per share also show a healthy upward trajectory, culminating in $7.01 for the latest quarter. This demonstrates the company’s operational strength and ability to grow its top and bottom lines.
π Growth Drivers β What Moves the Stock
- Robust Healthcare Demand π’ Upside Surprise β As a leading provider of acute care and behavioral health services, UHS benefits from consistent and growing demand for healthcare. An aging population and increasing access to care underpin a stable revenue stream.
- Behavioral Health Expansion π’ Upside Surprise β UHS is a dominant player in the behavioral health sector, a segment experiencing significant growth and reduced stigma. Continued investment and expansion in this area offer a clear runway for future revenue and earnings growth.
- Operational Efficiency π‘ Priced In β Despite macro pressures, UHS has demonstrated an ability to manage costs and maintain healthy margins. Ongoing efficiency initiatives could further boost profitability, especially as patient volumes recover.
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 6,486 |
| First Eagle Investment Management, LLC | 4,313 |
| Blackrock Inc. | 4,278 |
| State Street Corporation | 2,605 |
| Pzena Investment Management LLC | 2,112 |
| FMR, LLC | 1,829 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MILLER MARC D | Chief Executive Officer | Mar 26, 2026 | Activity | 29,715 |
| PETERSON MATTHEW JAY | Officer | Mar 26, 2026 | Activity | 5,627 |
| SIM EDWARD H. | Officer | Mar 26, 2026 | Activity | 6,404 |
| FILTON STEVEN G. | Chief Financial Officer | Mar 26, 2026 | Activity | 6,850 |
| MILLER ALAN B | Officer, Director and Beneficial Owner | Mar 26, 2026 | Activity | 14,153 |
| SUSSMAN ELLIOT J | Director | Mar 13, 2026 | Activity | 674 |
| SUSSMAN ELLIOT J | Director | Mar 13, 2026 | Activity | 2,500 |
| MILLER MARC D | Chief Executive Officer | Mar 12, 2026 | Activity | 63,036 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.0 |
β Key Risk Factors
π€ Given the strong bearish technical trend and macro headwinds, how much of a margin of safety does the current valuation offer against these persistent risks?
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $320 | $248.76 | $212 | 17 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Wells Fargo | Equal-Weight | Mar 2026 | main | |
| Cantor Fitzgerald | Neutral | Feb 2026 | main | |
| Barclays | Overweight | Feb 2026 | main | |
| TD Cowen | Buy | Jan 2026 | main | |
| Guggenheim | Buy | Dec 2025 | main |
The analyst community holds a strong Buy consensus for UHS, with the mean target implying a substantial 37% upside from current levels. Despite some recent downgrades to ‘Equal-Weight’ or ‘Neutral,’ the overall sentiment remains optimistic, suggesting analysts view the recent pullback as temporary.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Deeply oversold RSI (28.1) signals an imminent technical bounce, supported by an open bullish FVG near current price.
- Robust demand for healthcare services and strategic expansion in behavioral health provide a stable growth trajectory, undervalued by current market sentiment.
- Extremely low short interest (0.0%) removes a significant overhang, allowing for a cleaner rebound once buying momentum returns.
π Base Case
The base case assumes UHS continues its steady operational performance, benefiting from healthcare demand while navigating cost pressures. We project a gradual recovery towards analyst consensus, with the stock trading at a fair value reflecting its historical P/E multiple.
π» Bear Case
- Persistent labor shortages and wage inflation continue to erode operating margins, leading to weaker-than-expected earnings.
- Aggressive share buybacks exceeding free cash flow strain liquidity and necessitate increased debt, raising concerns about financial stability.
- A breakdown below key technical support levels, particularly the Value Area low of $163.17, could trigger further capitulation and a deeper sell-off.
π― Investor Action Plan β By Profile
Swing traders should consider an entry within the $178.00-$181.00 bullish FVG, targeting a quick bounce to the $195-$200 range (SMA50/200). A tight stop-loss at $175.00 is crucial given the prevailing bearish trend.
Position investors have a compelling entry window below $181.00, scaling into the position as long as the stock holds above $175.00. The goal is to capture the eventual mean reversion towards the analyst consensus target, holding for 3-6 months.
Long-term investors should initiate a position in UHS, leveraging the current undervaluation and strong industry tailwinds in healthcare and behavioral health. This dip represents an opportunity to accumulate shares of a quality operator at a significant discount, with a multi-year horizon.
β Investor FAQ β People Also Ask
Q: Why is UHS trading so low despite a ‘Buy’ consensus?
UHS’s recent price action reflects broader market pressures and sector-specific concerns like labor costs, rather than a fundamental deterioration. The current price is a significant discount to analyst targets, indicating a potential overreaction to temporary headwinds.
Q: What are the key technical levels to watch for a rebound?
Watch for a decisive break above the 50-day SMA at $202.52, which would signal a shift in short-term momentum. On the downside, the bullish FVG at $178.09-$181.05 must hold to prevent further declines, with a critical support at the Value Area low of $163.17.
Q: Is the low short interest a positive sign?
Absolutely. With 0.0% short interest, UHS lacks a significant bearish overhang from short sellers. This means less potential selling pressure and a higher likelihood of a clean rally if positive catalysts emerge, as there are no large short positions to cover.
π Want to check the current price action yourself?
π Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The views expressed are solely those of the analyst and may change without notice.
All active positions and their real-time performance are tracked on our Investment Log.
#UHS #UniversalHealthServices #HealthcareStocks #StockAnalysis #ValueInvesting #OversoldStocks #NYSE #Veqtio